Bristol-Myers, ImClone Partnership No Longer Threatened

02/28/2002 | Wall Street Journal, The

Bristol-Myers Squibb reportedly has abandoned its threat to break off its marketing partnership with ImClone. Fears over ImClone's cancer drug Erbitux were quelled, company officials said, after a successful meeting Tuesday between ImClone and the FDA. A source said Bristol-Myers still wants to renegotiate the partnership, but an ImClone spokesman said, "We intend to work under the existing terms."

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ